4D Molecular Therapeutics, Inc. (FDMT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 35M 70M 105M Q4 '21: 18M Q1 '22: 17.3M Q2 '22: 2.8M Q3 '22: 2M Q4 '22: 3.1M Q1 '23: 2.2M Q2 '23: 2.3M Q3 '23: 22M Q4 '23: 20.7M Q1 '24: 20.5M Q2 '24: 20.2M Q3 '24: 17K Q4 '24: 37K Q1 '25: 23K Q2 '25: 33K Q3 '25: 120K Q4 '25: 85.2M Q1 '26: 88.2M Q2 '26: 92M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-240M -160M -80M 0 80M 160M 240M Q4 '20: -56.7M Q1 '21: -59.7M Q2 '21: -52.1M Q3 '21: -67M Q4 '21: -71.3M Q1 '22: -81.4M Q2 '22: -102.2M Q3 '22: -106.1M Q4 '22: -110M Q1 '23: -113.7M Q2 '23: -117.5M Q3 '23: -104.9M Q4 '23: -112.9M Q1 '24: -120.9M Q2 '24: -131.2M Q3 '24: -168.4M Q4 '24: -187.8M Q1 '25: -203.3M Q2 '25: -220.3M Q3 '25: -230.4M Q4 '25: -159.5M Q1 '26: -179.5M Q2 '26: -197.1M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-240M -160M -80M 0 80M 160M 240M Q4 '20: -56.7M Q1 '21: -59.9M Q2 '21: -52.4M Q3 '21: -66.8M Q4 '21: -71.3M Q1 '22: -81.2M Q2 '22: -101.7M Q3 '22: -105.2M Q4 '22: -107.5M Q1 '23: -109.8M Q2 '23: -111.4M Q3 '23: -95.9M Q4 '23: -100.8M Q1 '24: -104.6M Q2 '24: -109.9M Q3 '24: -143.5M Q4 '24: -160.9M Q1 '25: -176.4M Q2 '25: -196.1M Q3 '25: -209.2M Q4 '25: -140.1M Q1 '26: -160.9M Q2 '26: -179.2M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-210M -140M -70M 0 70M 140M 210M Q4 '20: -50.9M Q1 '21: -52.4M Q2 '21: -62.4M Q3 '21: -64.8M Q4 '21: -69.1M Q1 '22: -77.3M Q2 '22: -81M Q3 '22: -86.3M Q4 '22: -86.7M Q1 '23: -91M Q2 '23: -93.2M Q3 '23: -73.4M Q4 '23: -75.8M Q1 '24: -77M Q2 '24: -85.2M Q3 '24: -113.4M Q4 '24: -134.6M Q1 '25: -153.3M Q2 '25: -166.4M Q3 '25: -183.5M Q4 '25: -109.1M Q1 '26: -129.4M Q2 '26: -156.1M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-210M -140M -70M 0 70M 140M 210M Q4 '20: -51.9M Q1 '21: -53.3M Q2 '21: -64M Q3 '21: -69.3M Q4 '21: -78.2M Q1 '22: -92.2M Q2 '22: -97.2M Q3 '22: -101.8M Q4 '22: -98.2M Q1 '23: -97.2M Q2 '23: -98.1M Q3 '23: -76.7M Q4 '23: -78.6M Q1 '24: -79.4M Q2 '24: -87.2M Q3 '24: -116.8M Q4 '24: -138.4M Q1 '25: -157M Q2 '25: -169.8M Q3 '25: -185.1M Q4 '25: -109.6M Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q2 '21: 26.7M Q3 '21: 27M Q1 '22: 32.2M Q2 '22: 32.3M Q3 '22: 32.4M Q1 '23: 32.7M Q2 '23: 38.3M Q3 '23: 42.3M Q1 '24: 49.3M Q2 '24: 55.3M Q3 '24: 55.6M Q1 '25: 55.7M Q2 '25: 55.9M Q3 '25: 56.1M Q1 '26: 68.1M Q2 '26: 70.3M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-9.00 -6.00 -3.00 0.00 3.00 6.00 9.00 Q4 '20: -8.82 Q1 '21: -6.89 Q2 '21: -4.25 Q3 '21: -3.56 Q4 '21: -2.56 Q1 '22: -2.77 Q2 '22: -3.36 Q3 '22: -3.33 Q4 '22: -3.32 Q1 '23: -3.38 Q2 '23: -3.28 Q3 '23: -2.73 Q4 '23: -2.66 Q1 '24: -2.44 Q2 '24: -2.30 Q3 '24: -2.85 Q4 '24: -2.98 Q1 '25: -3.18 Q2 '25: -3.53 Q3 '25: -3.75 Q4 '25: -2.42 Q1 '26: -2.57 Q2 '26: -2.63 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.